Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Free Cash Flow (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Free Cash Flow for 15 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 26.18% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$698000.0 through Dec 2025, down 445.54% year-over-year, with the annual reading at -$2.2 million for FY2025, 26.09% down from the prior year.
  • Free Cash Flow for Q4 2025 was $3.7 million at Aytu Biopharma, up from -$618000.0 in the prior quarter.
  • The five-year high for Free Cash Flow was $9.4 million in Q2 2023, with the low at -$9.1 million in Q3 2022.
  • Average Free Cash Flow over 5 years is -$1.5 million, with a median of -$1.1 million recorded in 2024.
  • The sharpest move saw Free Cash Flow soared 2247.41% in 2024, then crashed 2468.5% in 2025.
  • Over 5 years, Free Cash Flow stood at -$8.8 million in 2021, then skyrocketed by 72.21% to -$2.5 million in 2022, then skyrocketed by 94.49% to -$135000.0 in 2023, then skyrocketed by 2247.41% to $2.9 million in 2024, then rose by 26.18% to $3.7 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $3.7 million, -$618000.0, and $2.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.